EA202091737A1 - Производные индола и бензимидазола в качестве двойных антагонистов рецепторов 5-ht2a и 5-ht6 - Google Patents
Производные индола и бензимидазола в качестве двойных антагонистов рецепторов 5-ht2a и 5-ht6Info
- Publication number
- EA202091737A1 EA202091737A1 EA202091737A EA202091737A EA202091737A1 EA 202091737 A1 EA202091737 A1 EA 202091737A1 EA 202091737 A EA202091737 A EA 202091737A EA 202091737 A EA202091737 A EA 202091737A EA 202091737 A1 EA202091737 A1 EA 202091737A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ht2a
- indol
- receptors
- benzimidazole derivatives
- piperazin
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101150104779 HTR2A gene Proteins 0.000 title 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- JPCLIJVNHPXEPO-UHFFFAOYSA-N 4-piperazin-1-yl-2-(trifluoromethyl)-1H-indole Chemical class N1(CCNCC1)C1=C2C=C(NC2=CC=C1)C(F)(F)F JPCLIJVNHPXEPO-UHFFFAOYSA-N 0.000 abstract 1
- QDRDWSCTKAJVAS-UHFFFAOYSA-N 4-piperazin-1-yl-2-(trifluoromethyl)-1h-benzimidazole Chemical class C1=CC=C2NC(C(F)(F)F)=NC2=C1N1CCNCC1 QDRDWSCTKAJVAS-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Настоящее изобретение относится к новым 4-(пиперазин-1-ил)-2-(трифторметил)-1H-индолам и 4-(пиперазин-1-ил)-2-(трифторметил)-1H-бензимидазолам, представленным формулой (I), где все символы и переменные являются такими, как определено в описании. Соединения могут найти применение в способе предупреждения и/или лечения заболеваний, выбранных из группы, состоящей из болезни Альцгеймера, болезни Паркинсона, деменции с тельцами Леви, психоза, связанного с деменцией, шизофрении, бредовых синдромов и других психотических состояний, связанных и не связанных с приемом психоактивных веществ, депрессии, тревожных расстройств различной этиологии, нарушений сна различной этиологии.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18461519.3A EP3530651A1 (en) | 2018-02-21 | 2018-02-21 | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
| PCT/EP2019/054171 WO2019162306A1 (en) | 2018-02-21 | 2019-02-20 | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091737A1 true EA202091737A1 (ru) | 2020-10-12 |
Family
ID=61256878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091737A EA202091737A1 (ru) | 2018-02-21 | 2019-02-20 | Производные индола и бензимидазола в качестве двойных антагонистов рецепторов 5-ht2a и 5-ht6 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11034688B2 (ru) |
| EP (2) | EP3530651A1 (ru) |
| JP (1) | JP7200258B2 (ru) |
| KR (1) | KR20200123416A (ru) |
| CN (1) | CN112041300B (ru) |
| AU (1) | AU2019223036B2 (ru) |
| BR (1) | BR112020016972B1 (ru) |
| CA (1) | CA3088827A1 (ru) |
| DK (1) | DK3755688T3 (ru) |
| EA (1) | EA202091737A1 (ru) |
| ES (1) | ES2953815T3 (ru) |
| FI (1) | FI3755688T3 (ru) |
| HR (1) | HRP20230793T1 (ru) |
| HU (1) | HUE063564T2 (ru) |
| IL (1) | IL276762B2 (ru) |
| LT (1) | LT3755688T (ru) |
| MX (1) | MX2020008745A (ru) |
| PL (1) | PL3755688T3 (ru) |
| PT (1) | PT3755688T (ru) |
| RS (1) | RS64459B1 (ru) |
| SG (1) | SG11202007091XA (ru) |
| SI (1) | SI3755688T1 (ru) |
| UA (1) | UA126252C2 (ru) |
| WO (1) | WO2019162306A1 (ru) |
| ZA (1) | ZA202005747B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530651A1 (en) | 2018-02-21 | 2019-08-28 | Adamed sp. z o.o. | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
| CN115850204B (zh) * | 2022-11-26 | 2024-01-19 | 烟台大学 | 四氢苯并噻吩衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007006677A1 (en) | 2005-07-13 | 2007-01-18 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives as 5-ht6,5-ht24 |
| CA2668959A1 (en) * | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Indole and benzofuran 2-carboxamide derivatives |
| BRPI0718736A2 (pt) | 2007-01-08 | 2014-03-25 | Suven Life Sciences Ltd | " compostos inovadores de 4- (heterociclila) alquila -n- (arilasulfonila) indolo e seu uso como ligantes de 5ht6" |
| UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| PL395469A1 (pl) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego |
| CN104822264A (zh) | 2012-06-22 | 2015-08-05 | Map药物公司 | 新的卡麦角林衍生物 |
| EP3530651A1 (en) * | 2018-02-21 | 2019-08-28 | Adamed sp. z o.o. | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
-
2018
- 2018-02-21 EP EP18461519.3A patent/EP3530651A1/en not_active Withdrawn
-
2019
- 2019-02-20 FI FIEP19706271.4T patent/FI3755688T3/fi active
- 2019-02-20 BR BR112020016972-2A patent/BR112020016972B1/pt active IP Right Grant
- 2019-02-20 KR KR1020207022525A patent/KR20200123416A/ko active IP Right Grant
- 2019-02-20 CN CN201980027105.7A patent/CN112041300B/zh active Active
- 2019-02-20 PT PT197062714T patent/PT3755688T/pt unknown
- 2019-02-20 PL PL19706271.4T patent/PL3755688T3/pl unknown
- 2019-02-20 IL IL276762A patent/IL276762B2/en unknown
- 2019-02-20 SG SG11202007091XA patent/SG11202007091XA/en unknown
- 2019-02-20 DK DK19706271.4T patent/DK3755688T3/da active
- 2019-02-20 RS RS20230676A patent/RS64459B1/sr unknown
- 2019-02-20 ES ES19706271T patent/ES2953815T3/es active Active
- 2019-02-20 CA CA3088827A patent/CA3088827A1/en active Pending
- 2019-02-20 US US16/970,871 patent/US11034688B2/en active Active
- 2019-02-20 EA EA202091737A patent/EA202091737A1/ru unknown
- 2019-02-20 AU AU2019223036A patent/AU2019223036B2/en active Active
- 2019-02-20 EP EP19706271.4A patent/EP3755688B1/en active Active
- 2019-02-20 WO PCT/EP2019/054171 patent/WO2019162306A1/en active Application Filing
- 2019-02-20 LT LTEPPCT/EP2019/054171T patent/LT3755688T/lt unknown
- 2019-02-20 JP JP2020544234A patent/JP7200258B2/ja active Active
- 2019-02-20 HU HUE19706271A patent/HUE063564T2/hu unknown
- 2019-02-20 HR HRP20230793TT patent/HRP20230793T1/hr unknown
- 2019-02-20 MX MX2020008745A patent/MX2020008745A/es unknown
- 2019-02-20 SI SI201930608T patent/SI3755688T1/sl unknown
- 2019-02-20 UA UAA202005367A patent/UA126252C2/uk unknown
-
2020
- 2020-09-16 ZA ZA2020/05747A patent/ZA202005747B/en unknown
-
2021
- 2021-05-20 US US17/326,159 patent/US11981668B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY194461A (en) | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| PE20190913A1 (es) | Derivados aromaticos de sulfonamida | |
| TN2015000382A1 (en) | Perfluorinated cyclopropyl fused 1,3- oxazin -2- amine compounds as beta- secretase inhibitors and methods of use | |
| ATE493407T1 (de) | 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen | |
| NO20061137L (no) | Cyklopropylderivater som NK3-reseptorantagonister | |
| NI200900203A (es) | Sales novedosas de piperazina como antagonistas d3/d2. | |
| CA2537598A1 (en) | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | |
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
| MX2017001794A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. | |
| MX2009008773A (es) | Derivados de 3,4-dihidro-1,4-benzoxazina,3,4-dihidro-1,4-benzotiaz ina y 1,2,3,4-tetrahidro-quinoxalina como agonistas de adrenoreceptores alfa2c. | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| ATE519762T1 (de) | Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung | |
| MX2009013885A (es) | Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico. | |
| UA107080C2 (uk) | Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну | |
| EA202091737A1 (ru) | Производные индола и бензимидазола в качестве двойных антагонистов рецепторов 5-ht2a и 5-ht6 | |
| MX2019007103A (es) | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| MX2019007102A (es) | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. | |
| ATE443707T1 (de) | Isoxazolin-indol-derivate mit verbesserter antipsychotischer und anxiolytischer aktivität | |
| MX2019015606A (es) | Nuevos usos de un antagonista del receptor 5-ht6 puro. |